BISPECIFIC ANTIBODY-MEDIATED TARGETING OF NIDO-CARBORANES TO HUMAN COLON-CARCINOMA CELLS

Boron neutron capture therapy, a binary form of cancer treatment, has the potential to deliver potent cytotoxic radiation to tumor cells wit h minimal collateral damage to normal tissues if methods for the selec tive accretion of elevated concentrations of boron-10 in tumor can be developed. In this regard, a monoclonal antibody with dual specificity , for both anionic boron cluster compounds (nido-carboranes) and a tum or-associated antigen (carcinoembryonic antigen, CEA), was produced. T he specific binding of a nido-carborane to CEA-expressing tumor cells was achieved using this bispecific antibody. The ability of this bispe cific antibody to concentrate selectively at tumor sites in vivo has a lso been demonstrated, thus suggesting its potential for sequestering boron-rich compounds in tumors.